Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial.
PURPOSE: Patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) face an unfavorable prognosis once first-line treatment fails; therefore, there is an unmet need for new treatment options. RESULTS: In total, 255 patients were randomly assigned to receive Pola-R-GemOx (n = 129) or R-GemOx (n = 126).
PURPOSE: Patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) face an unfavorable prognosis once first-line treatment fails; therefore, there is an unmet need for new treatment options. RESULTS: In total, 255 patients were randomly assigned to receive Pola-R-GemOx (n = 129) or R-GemOx (n = 126).
What the study was
- Study design
- Randomized controlled trial
- Sample size
- 15
- Category
- Drug Development
- Maturity
- Potentially Practice-Changing
- Journal
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Why it surfaced
High-priority Rare diseases with high unmet need study: novel treatment potential warrants immediate pipeline escalation.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.